Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens

Diagnostic Cytopathology

Volumn 33, Issue 6, 2005, Pages 376-380

  Lin, Fan ^a   Shen, Ting ^b   Prichard, Jeffrey W ^a  

^a GEISINGER MEDICAL CENTER   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

Breast carcinoma; Chromogenic in situ hybridization (CISH); Cytology; Her 2 neu

Indexed keywords

DNA;

ARTICLE; ASPIRATION BIOPSY; BREAST BIOPSY; BREAST CARCINOMA; CHROMOGENIC IN SITU HYBRIDIZATION; CLINICAL ARTICLE; DNA PROBE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; ONCOGENE; ONCOGENE NEU; PRIORITY JOURNAL;

BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION; RECEPTOR, ERBB-2;

EID: 28844462979     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/dc.20401     Document Type: Article

References (20)

1. Slamon DJ, Clark GM. Amplification of c-erbB-2-B2 and aggressive human breast tumors? Science 1988;240:1795-1798.
2. DePotter CR. The neu-oncogene: more than a prognostic indicator? Hum Pathol 1994;25:1264-1268.
3. Ross JS, Fletcher JA. The Her-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 1999;9: 125-138.
4. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999:112(Suppl 1):S53-S67.
5. Varshney D, Zhou YY. Geller SA, Alsabeh R. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HerceptTest and PathVysion FISH assay. Am J Clin Pathol 2004;121: 70-77.
6. Lal P, Salazar PA, Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2.279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 2004;121:631-636.
7. Pauletti G, Dandekar S, Rong H. et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-3664.
8. Pauletti G, Godolphin W, Press M, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
9. Cell Markers and Cytogenetics Committees College of American Pathologists. Clinical Laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 2002;126:803-808.
10. Hanna W. Testing for HER2 status. Oncology 2001;61(Suppl 2):22-30.
11. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;157:1467-1472.
12. Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T, Ichinohasama R. Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int 2001;51:579-584.
13. Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 2002;82:1007-1014.
14. Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z. Determination of HER2 gene amplification by Chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 2002;15(6):657-665.
15. Arnould A, Denoux Y, MacGrogan G. et al. Agreement between chromogenic in situ hybridization (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 2003;88:1587-1591.
16. Gupta D, Middleton LP, Whitaker M, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 2003;119: 381-387.
17. Bozzetti C, Nizzoli R, Guazzi A, et al. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol 2002;13:1398-1403.
18. Tsukamoto F, Miyoshi Y, Koyama H, et al. Detection of chromosomal aneusomy by fluorescence in situ hybridization in fine-needle aspirates from breast tumors: application to the preoperative diagnosis of breast carcinoma. Cancer 2000;90:373-378.
19. Mezzelani A, Alasio L, Bartoli C, et al. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological tine-needle aspirates. Br J Cancer 1999;80:519-525.
20. Moore JG, To V, Patel SJ, Sneige N. HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections. Diagn Cytopathol 2000;23:299-302.